|121.63 0.14 (0.12%)||12-06 16:00|
|Targets||6-month :||146.7||1-year :||157.07|
|Resists||First :||125.6||Second :||134.47|
|Supports||First :||111.25||Second :||92.56|
|MAs||MA(5) :||120.38||MA(20) :||120.48|
|MA(100) :||130.59||MA(250) :||137.26|
|MACD||MACD :||-2.1||Signal :||-2.6|
|%K %D||K(14,3) :||69.4||D(3) :||62.2|
|52-week||High :||160.96||Low :||111.25|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ JAZZ ] has closed below upper band by 34.4%. Bollinger Bands are 3.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||122.99 - 123.36||123.36 - 123.76|
|Low:||119.79 - 120.24||120.24 - 120.74|
|Close:||120.84 - 121.52||121.52 - 122.27|
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||63 (M)|
|Shares Float||61 (M)|
|Held by Insiders||2.5 (%)|
|Held by Institutions||93.9 (%)|
|Shares Short||2,570 (K)|
|Shares Short P.Month||2,610 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||55.43|
|Profit Margin||2.1 %|
|Operating Margin||17.7 %|
|Return on Assets (ttm)||5.9 %|
|Return on Equity (ttm)||2.5 %|
|Qtrly Rev. Growth||3.2 %|
|Gross Profit (p.s.)||53.84|
|Sales Per Share||60.19|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||1,270 (M)|
|Levered Free Cash Flow||1,100 (M)|
|Price to Book value||2.19|
|Price to Sales||2.02|
|Price to Cash Flow||6.02|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|